Early ADME in support of drug discovery: the role of metabolic stability studies
- PMID: 11465046
- DOI: 10.2174/1389200003339018
Early ADME in support of drug discovery: the role of metabolic stability studies
Abstract
The area of Drug Discovery has undergone an amazing evolution in the past decade. This evolution is typified by the development of automated combinatorial synthesis and high throughput pharmacological testing. This, in turn, has lead to the ability to create and mine extensive databases and then model this new information. The overall result is a substantial increase in the rate of target identification, generation of new leads, and finally, optimization of those leads into clinical candidates. ADME studies have always played a critical role in helping to optimize the pharmacokinetic (PK) properties of new drugs thereby increasing their success rate. As a consequence of the increased throughput of drug discovery, ADME studies have evolved to keep pace. These so-called "early ADME" studies, are characterized by parallel processing and higher throughput than before. A primary concern of medicinal chemists is to design molecules that will have not only the desired activity, but also suitable potency and duration of action, which is influenced by pharmacokinetic properties such as bioavailability and half-life. This article focuses on a particular subset of eADME studies known as "metabolic stability", which can be an important contributor for a good pharmacokinetic profile. Metabolic stability studies represent the adaptation of more complex metabolism rate studies to a minimized system suitable for parallel processing of large numbers of compounds. The theoretical basis for metabolic stability lies in its relationship to the concept of metabolic intrinsic clearance. Typical metabolic stability protocols are discussed with respect to their relation to drug design. How metabolic stability studies have evolved to keep pace with advances in drug discovery is also discussed. Several case studies of the role of metabolic stability in drug design over the past few years are summarized to exemplify the utility of this kind of study. Finally, future trends in drug metabolism and analytical chemistry and how they may influence metabolic stability studies are reviewed.
Similar articles
-
Optimization of metabolic stability as a goal of modern drug design.Med Res Rev. 2001 Sep;21(5):412-49. doi: 10.1002/med.1017. Med Res Rev. 2001. PMID: 11579441 Review.
-
Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.Clin Pharmacokinet. 2003;42(6):515-28. doi: 10.2165/00003088-200342060-00002. Clin Pharmacokinet. 2003. PMID: 12793837 Review.
-
Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.Curr Drug Metab. 2006 Feb;7(2):165-82. doi: 10.2174/138920006775541552. Curr Drug Metab. 2006. PMID: 16472106 Review.
-
Applications of high-throughput ADME in drug discovery.Curr Opin Chem Biol. 2004 Jun;8(3):339-45. doi: 10.1016/j.cbpa.2004.04.015. Curr Opin Chem Biol. 2004. PMID: 15183334 Review.
-
In Silico and Ex silico ADME approaches for drug discovery.Curr Top Med Chem. 2002 Dec;2(12):1287-304. doi: 10.2174/1568026023392841. Curr Top Med Chem. 2002. PMID: 12470281 Review.
Cited by
-
AI-Driven Enhancements in Drug Screening and Optimization.Methods Mol Biol. 2024;2714:269-294. doi: 10.1007/978-1-0716-3441-7_15. Methods Mol Biol. 2024. PMID: 37676604
-
Natural coumarins from Murraya paniculata as mixed-type inhibitors of cholinesterases: In vitro and in silico investigations.Front Pharmacol. 2023 Mar 9;14:1133809. doi: 10.3389/fphar.2023.1133809. eCollection 2023. Front Pharmacol. 2023. PMID: 36969847 Free PMC article.
-
A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling.Assay Drug Dev Technol. 2020 May/Jun;18(4):157-179. doi: 10.1089/adt.2020.970. Epub 2020 May 14. Assay Drug Dev Technol. 2020. PMID: 32407132 Free PMC article.
-
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures.J Med Chem. 2015 May 14;58(9):4066-72. doi: 10.1021/acs.jmedchem.5b00104. Epub 2015 Apr 22. J Med Chem. 2015. PMID: 25860834 Free PMC article.
-
Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.Perspect Medicin Chem. 2007 Jun 26;1:1-9. Perspect Medicin Chem. 2007. PMID: 19812732 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous